Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.
Not Applicable
Completed
- Conditions
- Natural Killer Cell Cytokine ProductionERASLidocaineCancer of Pancreas
- Registration Number
- NCT05470166
- Lead Sponsor
- Alexandria University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria:<br><br> 1. Age 30-70 years<br><br> 2. Both sex.<br><br> 3. American society of anesthesiology (ASA) physical status class II;III.<br><br> 4. Resectable pancreatic tumors.<br><br>Exclusion Criteria:<br><br> 1. Patients with history of sensitivity to lidocaine,<br><br> 2. Diabetic patients.<br><br> 3. Body weight loss > 15%.<br><br> 4. Opioid tolerant patient or patient receiving nonsteroidal anti-inflammatory drugs<br> within 1 week of surgery or antiarrythmic drugs.<br><br> 5. Cognitive dysfunction.<br><br> 6. Any history of antitumor treatments or chemotherapy before surgery<br><br> 7. Any contraindication for neuraxial anaesthesia.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post-operative nociceptive pain assessment.
- Secondary Outcome Measures
Name Time Method Effect on immune response;Effect on i tumor recurrence;Total intra-operative fluid requirements.;Gastro-intestinal recovery.;Time to first ambulation;Total analgesic consumption;Length of hospital stay in days;Effect on haemodynamics;Effect on haemodynamics;Perioperative complications